Research on lung cancer detection and treatment. Covers microbial predictors of immunotherapy, MRI detection, microplastics, and RAS-mutant drugs.
Researchers discovered that blocking cell cycle inhibitor p21 prevents lung cancer cells from entering a quiescent state, allowing for more cancer cell death before and after chemotherapy. This leads to reduced cancer relapse rates, improving patient outcomes.
A review of 3,000 studies suggests microplastics in the air may cause serious health problems, including colon cancer, poor lung function, and infertility. The tiny plastic particles are believed to contribute to chronic pulmonary inflammation, increasing the risk of lung cancer.
A new diagnostic test uses a unique molecular 'finger print' to detect different types of cancer, with near-perfect accuracy, and could lead to earlier detection and improved patient outcomes. The test targets ribosomal RNA molecules, which are modified differently in healthy and diseased tissues.
Researchers combine a precision cancer drug with an antibody and radiation therapy to eliminate tumors without causing side effects. The approach uses the cancer drug as a molecular flag for cancerous cells, allowing immune cells to target them. This method has shown promise in eliminating lung cancer in mice with minimal side effects.
The study found that smokers with myelodysplastic syndromes (MDS) or precursor conditions had elevated levels of genetic mutations linked to the disease. Heavier smokers accumulated more mutations, and long-term smokers were more likely to show disease progression.
A national lung cancer screening program is proposed to reduce deaths and improve survival rates for Australian patients. The Flinders University study found that screening individuals aged 50-70 every two years would be cost-effective and add significant years of healthy life.
The study estimated that prevention, screening, and treatment efforts in the US led to an average of 8 out of 10 cancer deaths being avoided for breast, cervical, colorectal, lung, and prostate cancers combined. The total number of averted cancer deaths was approximately 5.94 million between 1975 and 2020.
The PoweRD 2 Cure ALK+ Lung Cancer TeamLab aims to identify and exploit vulnerabilities of leftover cancer cells to prevent recurrence. By combining new strategies, structures, and thinking from across disciplines, researchers hope to develop treatment strategies that leave no cancer cells alive.
The global lifetime risk of lung cancer is 3.49%, with high-risk countries like French New Caledonia and Canada, while low-HDI countries have lower risks due to shorter lifespans and limited resources. After 40, the risk drastically increases, but residual risk decreases with age.
Researchers found that as cells age, they lose regenerative capacity and become less susceptible to cancer. The study's findings suggest that therapies targeting ferroptosis may be less effective in older patients.
Researchers have identified UBA1 enzyme as key mediator for immune response to tumors, inhibiting its activity increases T-cell recruitment and lowers tumor resistance. Pairing UBA1 inhibitors with immune checkpoint blockade therapies may make immunotherapy more effective for patients with 'cold' tumors.
A new study reveals that lung cancer screening CTs can detect coronary artery disease in 83% of cases, with high levels found in 30%. This finding highlights the potential benefits of lung cancer screening for identifying and managing cardiovascular risk factors.
A series of five papers highlights critical public health challenges related to cancer control in eight SAARC countries and the Rohingya refugee population in Bangladesh. The studies identify barriers contributing to significant disparities in cancer outcomes and actionable solutions to address these challenges.
This study compares the pharmacokinetics of aumolertinib, osimertinib, and gefitinib in mouse models and NSCLC patients. Aumolertinib exhibits better pharmacokinetic profiles, with higher concentrations in plasma and tissues, making it a promising candidate for EGFR mutation-positive NSCLC treatment.
The IASLC and LCRF have awarded a $2.5 million team science grant to Dr. David Barbie's research team to develop an immune-based approach to target drug-resistant lung cancer cells. The project aims to harness the body's immune system to eliminate persister cells, which contribute to disease progression.
Sylvester researchers will present over 130 studies at ASH 2024, addressing disparities in gastric cancer. Frank J. Penedo's research highlights worse outcomes for patients with unmet supportive needs, while Shria Kumar's work seeks answers for disparities in gastric cancer among specific minorities.
Scientists use machine learning-based classifiers to differentiate lung cancer and noncancer based on urinary miRNA ensembles. The study reveals high specificity and sensitivity in detecting early-stage lung cancer, offering new hope for improved patient outcomes.
A study by Niigata University found that AI analysis of PET/CT images can predict the occurrence of interstitial lung disease, a serious side effect of immunotherapy. Patients with high inflammation in non-cancerous lungs are at a higher risk of developing this condition.
Researchers successfully delivered anti-cancer ASO molecules to lung tumor sites using human red blood cells, demonstrating potent anti-cancer effects against NSCLC. The approach utilizes EGFR-targeting moieties to home in on cancerous cells, offering a potentially powerful treatment modality for personalized cancer medicine.
Researchers at MD Anderson Cancer Center present promising new treatments, including a gastric cancer therapy using T cell antigen coupler technology. Additionally, COVID-19 mRNA vaccines are shown to improve responses to immune checkpoint inhibitors in patients with non-small cell lung and melanoma cancers.
A new study published in The British Journal of Cancer found that whole genome sequencing can help identify treatment recommendations for cancer patients. The study evaluated the regional implementation of the 100,000 Genomes Project and found that different types of cancer were associated with varying rates of recommended actions.
Researchers have developed ultrasensitive sensors that can detect isoprene levels in the parts-per-billion range, a decline of which can indicate lung cancer. The sensors, made with indium oxide-based nanoflakes, showed promise in distinguishing lung cancer patients from healthy individuals.
A joint research team at Korea University College of Medicine announced the world's first comparative results of single-port robotic thymectomy, showing a lower conversion rate to multi-port surgery and shorter hospital stays. The study demonstrated that single-port robotic thymectomy is a safer alternative to traditional VATS thymectomy.
Researchers analyzed tumor samples from 64 SCLC patients, identifying promising results for biomarkers DLL3 and TTF-1. These biomarkers showed potential as targets for therapies like Tarlatamab and improved survival rates in patients with TTF-1-positive tumors.
A low-dose CT scan can pick up on early-stage lung cancers, which can often be completely removed with surgery. However, less than a fifth of those eligible for the test are getting it, highlighting awareness and communication gaps.
A new initiative, CAL-PALS, aims to expand access to life-saving lung cancer screening for marginalized groups in Los Angeles County. The program will engage physicians and staff to create system-level changes increasing access to high-quality services.
Researchers have developed a large-scale drug screening technique that tracks drug targets inside cells, allowing for the identification of potential new drugs. The technology screens candidate drugs 100 times faster than standard manual techniques, enabling the discovery of previously unknown drugs.
Researchers have discovered a therapeutic approach that shows promise in preclinical models for treating cancers driven by RAS mutations. The study found that tri-complex inhibitors can restore the normal functioning of mutated RAS proteins, aiming to correct the defect that drives cancer growth.
A recent study found that endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) provided sufficient tissue for identifying actionable genetic aberrations in patients with advanced non-small cell lung cancer. Liquid biopsy samples were also analyzed and compared to EBUS-TBNA results, demonstrating similar findings.
A new lung cancer screening initiative in Central Texas has successfully increased screenings among low-income and minority populations. The program's patient-centered approach, including bilingual support and no-cost screenings, resulted in an 83% completion rate of low-dose CT scans among eligible patients.
TYRA-300 shows promise in treating metastatic bladder cancer patients with FGFR3 gene mutations, achieving a 50% overall response rate and 100% disease control rate. The treatment also displays improved tolerability with lower side effects compared to existing pan-FGFR inhibitors.
Researchers have developed a 'mini-protein' that targets cancer cells expressing Nectin-4, allowing for direct delivery of radiation to tumours. The treatment shows promise in targeting multiple types of cancers and has the potential to be safe for repeated administrations.
A national report reveals nearly 18% of Canadian homes have radon levels above 200 Bq/m³, increasing lung cancer risk. Canadians are among the most highly exposed to radon, highlighting the need for urgent action to address this public health concern.
Researchers found that physically fitter patients with metastatic lung cancer live longer and respond better to chemotherapy. The study identified biomarkers in blood plasma that can indicate which patients are most likely to respond to treatment.
Researchers reported a complete and long-lasting response to immunotherapy in a stage IV non-small cell lung cancer patient with brain metastases. The patient achieved overall survival of 87 months and progression-free survival of 73 months after treatment sequencing.
A study at the University of Texas M.D. Anderson Cancer Center found that adding CTLA-4 immune checkpoint inhibitors to durvalumab and chemotherapy improved overall response rates, progression-free survival, and overall survival for patients with metastatic non-squamous non-small cell lung cancer harboring STK11 and/or KEAP1 mutations.
Researchers identified AM-101 as a potential new way to enhance radiation therapy for patients with lung cancer that has spread to the brain. The drug's ability to activate GABA(A) receptors increases autophagy in lung cancer cells, making them more sensitive to radiation treatment.
Researchers developed a microchip that captures exosomes from blood plasma to identify signs of lung cancer, achieving 10x faster detection and 14x greater sensitivity. The chip uses twisted gold nanoparticles to distinguish between healthy patients and those with lung cancer.
A new study suggests that banning the purchase of cigarettes and other tobacco products among people born between 2006 and 2010 could prevent an estimated 1.2 million lung cancer deaths in 185 countries by 2095. This could reduce the impact of smoking on lung cancer deaths in future generations.
The American College of Chest Physicians has released a new clinical guideline on endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) specimen processing and handling to standardize the process. The guidelines aim to improve diagnostic yield and specimen preservation for downstream ancillary testing.
UCLA investigators presented data on chemoradiotherapy in rectal cancer, MRI-guided radiotherapy for prostate cancer, and symptom self-reporting during treatment. Researchers developed a predictive model to identify patients most likely to respond to chemoradiotherapy in rectal cancer.
Researchers developed a mathematical model predicting enhanced survival outcomes for NSCLC patients with novel treatment combinations. The model neutralizes the negative effects of miR-155, boosting standard-of-care treatments like cisplatin and immune checkpoint inhibitors.
According to the Global Cancer Observatory (GLOBOCAN), lung cancer is the most common type of cancer, with 2.2 million new cases and 1.8 million deaths worldwide in 2020. China had the highest number of new cases, and incidence and mortality rates have been steadily rising from 1990 to 2019.
Researchers have tested a combination of treatments in mice with lung cancer and shown that these allow immunotherapies to target non-responsive tumours. The combination therapy allows 'immune cold' tumours to respond to the body's own defences.
A nonrandomized clinical trial found that wearable devices can increase moderate-to-vigorous physical activity and reduce dyspnea at 6 months post-lung cancer surgery. This suggests a promising role for wearable devices in personalizing perioperative rehabilitation strategies.
A new study by Boston University researchers found that the majority of social media posts from e-cigarette brands left out health warnings, despite a federal requirement to include them. The study used AI to analyze over 2,000 Instagram posts and discovered that only 13% complied with FDA health warning requirements.
A study published in JAMA Network Open found that body mass index (BMI) has a more complex relationship with mortality risk during cancer therapy than previously thought. For patients with advanced non-small cell lung cancer, higher BMI was associated with lower mortality when undergoing immunotherapy or conventional chemotherapy. Howe...
Researchers at NTU Singapore and Oxford have identified a new process called nucleophagy that helps cells remove harmful DNA-protein lesions, promoting genetic material stability and cell survival. This discovery may improve cancer treatment outcomes for patients with colorectal cancer.
A recent study published in JAMA found that telehealth delivery of early palliative care is equivalent to in-person care in terms of quality of life outcomes for patients with advanced non-small cell lung cancer. This finding highlights the potential benefits of expanding access to this evidence-based care model through telehealth.
A new study published in Cell found that TGF-beta and RAS signaling pathways are both required for lung cancer metastasis. Inhibiting RREB1, a transcription factor controlled by RAS, disabled the metastatic process in mouse models, suggesting it could be a potential new drug target.
Patients with chronic respiratory conditions like COPD and asthma may experience delays in being diagnosed with lung cancer due to obscured early symptoms. The study found significant delays in patients with comorbidities that provide alternative explanations for lung cancer symptoms.
Researchers have found that natural killer cells instinctively recognize and attack the XPO1 protein, which drives cancer growth. By targeting this protein, scientists may be able to activate more killer cells to destroy cancer cells. The study suggests that this approach could lead to personalized cancer treatment with less side effects.
Obesity-related cancer rates in China have risen sharply among young people, with an alarming 3.6% annual increase between 2007 and 2021. The trend is particularly pronounced among those aged 25-29, highlighting the urgent need for better public health policies to address China's growing overweight and obesity rates.
A new AI-based digital platform has been developed to analyze tissue sections from lung cancer patients, making diagnosis faster and more accurate. The platform uses algorithms that enable fully automated analysis of digitized tissue samples, allowing for personalized therapy based on molecularly specific genetic changes.
Researchers have identified HLA-E as a critical negative regulator of NK cell interactions with cancer cells. Disrupting NKG2A:HLA-E interactions may stimulate both NK cell and cytotoxic T cell effector functions against cancer, offering a promising anti-cancer strategy.
Researchers developed alternative criteria using a prediction model to identify people with the most to gain from lung cancer screening. The study found that high-benefit groups include those who smoked for a long duration but at a lower intensity, heavy smokers who quit over 15 years ago, and racial and ethnic minority groups.
A new approach combining machine and deep transfer learning improves the accuracy of diagnosing mediastinal lymph node metastases in lung cancer. The study developed a model that achieved strong classification performance even with limited datasets, enhancing healthcare management.
A recent study published in Radiology found that solid lung nodules were present in approximately 42% of non-smoking adults, with prevalence increasing with age. The study suggests that current nodule follow-up guidelines may lead to unnecessary follow-up examinations for low-risk individuals.
Researchers found that a simplified two-question test can predict smoking abstinence in cancer patients with equal accuracy as the full Fagerström Test. However, the test may not work well for Non-Hispanic Black people with a cancer diagnosis. The study aims to help doctors tailor tests for different groups.
A new treatment targeting two tumor-feeding genes is being tested to treat non-small cell lung cancer. The therapy, called PEPD-G278D, breaks down genetic mutations that contribute to drug resistance, showing strong suppression of NSCLC cell function and tumors.